Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             354 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Abnormal glycosylation of serum IgG from patients with ANCA-associated systemic vasculitis: Relation to disease activity Lardinois, O.
 2013
 42 4P2 p. 735-
1 p.
 artikel
2 Abundant neutrophil extracellular traps in thrombus of patient with microscopic polyangiitis Nakazawa, D.
 2013
 42 4P2 p. 755-
1 p.
 artikel
3 A case of eosinophilic granulomatosis with polyangiitis (EGPA) who relapsed with saddle nose Saito, M.
 2013
 42 4P2 p. 701-702
2 p.
 artikel
4 A case of lung biopsy-proven MPO-ANCA positive granulomatosis with polyangiitis (GPA; Wegener's granulomatosis) Murakami, K.
 2013
 42 4P2 p. 712-713
2 p.
 artikel
5 A case of relapse of Churg-Strauss syndrome (CSS) with crescentic lesions Yoshikazu, F.
 2013
 42 4P2 p. 696-
1 p.
 artikel
6 Acute respiratory distress syndrome (ARDS) as primary manifestation in ANCA-associated vasculitis Dolch, M.
 2013
 42 4P2 p. 752-753
2 p.
 artikel
7 ADAPTIV: A Delphi study to assess morbidity prevention and treatment in vasculitis Brown, N.
 2013
 42 4P2 p. 746-747
2 p.
 artikel
8 Aklides® – a highly versatile imaging platform for detection of ANCA Knütter, I.
 2013
 42 4P2 p. 686-
1 p.
 artikel
9 Alveolar hemorrhage, rectus muscle hematoma, and gastrointestinal bleeding accompanied by crescentic glomerulonephritis in a patient with PR3-ANCA disease Cao, Y.
 2013
 42 4P2 p. 709-710
2 p.
 artikel
10 A multicenter survey of rituximab for eosinophilic granulomatosis with polyangiitis (Churg-Strauss) Hot, A.
 2013
 42 4P2 p. 698-
1 p.
 artikel
11 A myelopoiesis gene signature during remission in ANCA-associated vasculitis reflects ongoing prednisolone therapy and does not seem to predict relapses Kurz, T.
 2013
 42 4P2 p. 662-
1 p.
 artikel
12 Analysis of whole-blood micro-rna profiles in PR-3-ANCA positive vasculitis Kirsch, T.
 2013
 42 4P2 p. 708-
1 p.
 artikel
13 ANCA-associated systemic vasculitis is associated with impaired dilatory capacity of the conduit brachial artery – a link to increased cardiovascular risk? Clausen, P.
 2013
 42 4P2 p. 723-724
2 p.
 artikel
14 ANCA-associated vasculitides (AAV) from the gender point of view Radice, A.
 2013
 42 4P2 p. 703-704
2 p.
 artikel
15 ANCA-associated vasculitis (AAV) and thrombotic michroangiopathies (TMA): A retrospective histological study Manenti, L.
 2013
 42 4P2 p. 672-
1 p.
 artikel
16 ANCA-associated vasculitis in Hispanics: An unrecognized severity Sreih, A.
 2013
 42 4P2 p. 668-669
2 p.
 artikel
17 ANCA disease patients have defective Treg function exacerbated by expansion of a suppression-resistant effector population Free, M.
 2013
 42 4P2 p. 656-
1 p.
 artikel
18 ANCA disease patients with increased expression of autoantigen genes produce an alternative PR3 transcript and synthesize autoantigen proteins Alderman, E.
 2013
 42 4P2 p. 669-
1 p.
 artikel
19 ANCA epitope specificity determines pathogenicity, detectability and clinical predictive value Roth, A.
 2013
 42 4P2 p. 664-
1 p.
 artikel
20 ANCA in Auckland 1998–2008 De Zoysa, J.
 2013
 42 4P2 p. 702-703
2 p.
 artikel
21 ANCA-positive and ANCA-negative phenotypes of eosinophilic granulamatosis and polyangiitis (EGPA): Outcome and long-term follow-up of 46 patients from a single Polish centre Szczeklik, W.
 2013
 42 4P2 p. 699-700
2 p.
 artikel
22 ANCA reactive B cells and neutrophils cross-talk in the pathogenesis of AAV: A model proposal Hurtado, P.R.
 2013
 42 4P2 p. 760-
1 p.
 artikel
23 ANCA testing in routine clinical laboratory Lochman, I.
 2013
 42 4P2 p. 681-682
2 p.
 artikel
24 ANCA vasculitis and atypical hemolytic uremic syndrome: An association with poor outcome Gnappi, E.
 2013
 42 4P2 p. 752-
1 p.
 artikel
25 Aneurysms in the view of rheumatology perspective Karadag, O.
 2013
 42 4P2 p. 741-
1 p.
 artikel
26 An international, open label, randomised controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated vasculitis (RITAZAREM) Jayne, D.
 2013
 42 4P2 p. 768-
1 p.
 artikel
27 An open-label trial of abatacept in mild relapsing granulomatosis with polyangiitis (Wegener's) (GPA) Langford, C.
 2013
 42 4P2 p. 770-
1 p.
 artikel
28 Antibodies to LAMP-2 alter lysosome function and attenuate chaperone-mediated autophagy in human macrophages Sintiprungrat, K.
 2013
 42 4P2 p. 762-
1 p.
 artikel
29 Antineuthropil cytoplasmic autoantibody-associated vasculitis (AAV) in older patients (REVAS Study) Solans, R.
 2013
 42 4P2 p. 751-
1 p.
 artikel
30 Anti-neutrophil cytoplasmic antibodies associated vasculitis frequency in Dr. Manuel Quintela university hospital Rodriguez Sisniega, N.
 2013
 42 4P2 p. 704-
1 p.
 artikel
31 Anti TNF-α drug inhibits initial process of vasculitis in animal model of Kawasaki disease Oharaseki, T.
 2013
 42 4P2 p. 687-688
2 p.
 artikel
32 Aortic dissection in giant cell arteritis: A population-based study of predictors Kermani, T.
 2013
 42 4P2 p. 721-722
2 p.
 artikel
33 Aortitis evidenced by PET-CT 18FDG in the setting of ANCA-associated vasculitis: About four cases Nguyen, T.
 2013
 42 4P2 p. 736-
1 p.
 artikel
34 A randomized trial of mycophenolate mofetil versus cyclophosphamide for remission induction of ANCA-associated vasculitis: “MYCYC”. On behalf of the European vasculitis study group Jones, R.
 2013
 42 4P2 p. 678-679
2 p.
 artikel
35 Are anti-proteinase-3 ANCA a useful marker of granulomatosis with polyangiitis relapses? Results of a longitudinal study on 126 patients Thai, L.H.
 2013
 42 4P2 p. 682-
1 p.
 artikel
36 A risk score for predicting short-term incidence of death or relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis Maldini, C.
 2013
 42 4P2 p. 666-
1 p.
 artikel
37 A scoring tool for ear, nose and throat disease activity and damage in eosinophilic granulomatosis with polyangiitis (Churg-Strauss) Kureghian, J. Der
 2013
 42 4P2 p. 700-
1 p.
 artikel
38 A single centre experience of 40 children with Takayasu arteritis from India Goel, R.
 2013
 42 4P2 p. 728-729
2 p.
 artikel
39 Assessment of disease activity in large vessel vasculitis: Initial results of an international Delphi exercise Aydin, S.Z.
 2013
 42 4P2 p. 673-674
2 p.
 artikel
40 Assessment of patients with Takayasu's arteritis in a routine clinical follow-up with Indian Takayasu Clinical Activity Score (ITAS2010) Alibaz-Oner, F.
 2013
 42 4P2 p. 678-
1 p.
 artikel
41 Association between thyroid disease and ANCA associated vasculitis Prendecki, M.
 2013
 42 4P2 p. 739-740
2 p.
 artikel
42 Asymptomatic myocardial ischemic disease in Takayasu's arteritis: Detection by magnetic resonance imaging Comarmod, C.
 2013
 42 4P2 p. 728-
1 p.
 artikel
43 Autoantibodies for several antigens in neutrophil cytoplasm other than PR3 and MPO also promote release of NETs from neutrophils Komagata, Y.
 2013
 42 4P2 p. 762-
1 p.
 artikel
44 Behçet's disease and pregnancy Noel, N.
 2013
 42 4P2 p. 691-692
2 p.
 artikel
45 Behçet's disease in Budd-Chiari Syndrome Desbois, A.C.
 2013
 42 4P2 p. 676-
1 p.
 artikel
46 Behçet's disease in children: The Great Ormond Street Hospital experience Nanthapisal, S.
 2013
 42 4P2 p. 691-
1 p.
 artikel
47 Biologic agents offer an effective long-term therapeutic option for refractory Takayasu arteritis Youngstein, T.
 2013
 42 4P2 p. 677-678
2 p.
 artikel
48 Both histone methylation and acetylation contribute to the aberrant upregulation of proteinase 3 (PR3) and myeloperoxidase (MPO) genes in patients with ANCA disease Yang, J.
 2013
 42 4P2 p. 661-
1 p.
 artikel
49 B regulatory cells are numerically but not functionally impaired in AAV Todd, S.K.
 2013
 42 4P2 p. 658-
1 p.
 artikel
50 Calprotectin amplifies the inflammatory response Pepper, R.
 2013
 42 4P2 p. 651-
1 p.
 artikel
51 Can serum procalcitonin help to diagnose patients with new onset giant cell arteritis? Diamantopoulos, A.P.
 2013
 42 4P2 p. 722-
1 p.
 artikel
52 Cardiovascular outcomes and prognostic predictors in ANCA-associated vasculitis Yuste, C.
 2013
 42 4P2 p. 748-749
2 p.
 artikel
53 Cardiovascular risk in different variants of granulomatosis with polyangiitis (Wegener's) Kuznetsova, E.
 2013
 42 4P2 p. 707-708
2 p.
 artikel
54 C5aR inhibitor on leukocytes exploratory ANCA associated renal vasculitis (CLEAR) clinical trial with orally administered CCX168 Bruchfeld, A.
 2013
 42 4P2 p. 768-769
2 p.
 artikel
55 Central nervous system involvement in granulomatous polyangiitis (GPA) Karadag, O.
 2013
 42 4P2 p. 714-
1 p.
 artikel
56 Characteristics and outcome of patients with granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis on renal replacement therapy – Data from the ERA-EDTA registry Hruskova, Z.
 2013
 42 4P2 p. 675-
1 p.
 artikel
57 Characteristics and outcomes of patients with ANCA-associated vasculitis in the Czech population Hruskova, Z.
 2013
 42 4P2 p. 664-665
2 p.
 artikel
58 Characteristics of patients with infectious cryoglobulinemia vasculitis in the absence of HCV infection: Results from the French nationwide CryoVas survey Terrier, B.
 2013
 42 4P2 p. 694-
1 p.
 artikel
59 Characterization of drug-induced ANCA vasculitis at Massachusetts's general hospital (MGH): 1989–2012 Pendergraft, W.
 2013
 42 4P2 p. 654-655
2 p.
 artikel
60 Characterization of F-18 fluorodeoxyglucose PET/CT in granulomatosis with polyangiitis Nelson, D.
 2013
 42 4P2 p. 710-
1 p.
 artikel
61 Characterization of regulatory B cells in ANCA-associated vasculitis (AAV) Lepse, N.
 2013
 42 4P2 p. 755-756
2 p.
 artikel
62 Chronic asymptomatic aortic dissection (AD) in Takayasu's arteritis (TA); how to treat? Tosounidou, S.T.
 2013
 42 4P2 p. 730-
1 p.
 artikel
63 Chronic periaortitis and autoimmune thyroiditis: A novel association Urban, M.L.
 2013
 42 4P2 p. 725-
1 p.
 artikel
64 Circulating gamma delta T cells are significantly reduced in granulomatosis with polyangiitis Scollard, S.
 2013
 42 4P2 p. 716-
1 p.
 artikel
65 Circulating level of high mobility group box-1 is associated with disease activity in antineutrophil cytoplasmic autoantibody-associated vasculitis Wang, C.
 2013
 42 4P2 p. 757-758
2 p.
 artikel
66 Circulating microRNAs in ANCA vasculitis correlate to renal function, hemoglobin and risk of relapse Skoglund, C.
 2013
 42 4P2 p. 743-
1 p.
 artikel
67 Clinical and pathological study on 34 patients with primary ANCA-associated systemic vasculitis with renal immune complex deposition Li, X.
 2013
 42 4P2 p. 753-
1 p.
 artikel
68 Clinical assessment of asthma severity partially corresponds to sputum eosinophilic airway inflammation in allergic eosinophilic granulomatosis with polyangiitis Latorre, M.
 2013
 42 4P2 p. 697-
1 p.
 artikel
69 Clinical characteristics of ANCA associated vasculitis in hispanic patients: Single centre experience in Chile Cisternas, M.
 2013
 42 4P2 p. 744-
1 p.
 artikel
70 Clinical evaluation of a rapid immunofluorescence test (IIFT) for diagnosis of ANCA-associated vasculitis Radice,
 2013
 42 4P2 p. 663-
1 p.
 artikel
71 Clinical manifestations of granulomatosis with polyangiitis (Wegener's granulomatosis) in the upper respiratory tracts Iaremenko, O.
 2013
 42 4P2 p. 714-
1 p.
 artikel
72 Clinical value of commonly measured laboratory tests in eosinophilic granulomatosis with polyangiitis (Churg-Strauss) Grayson, P.
 2013
 42 4P2 p. 697-698
2 p.
 artikel
73 Cluster analysis to explore subclassification of eosinophilic granulomatosis with polyangiitis (Churg–Strauss) Neumann, T.
 2013
 42 4P2 p. 653-
1 p.
 artikel
74 Coagulation activity in renal ANCA-positive vasculitis Ekstrand, A.E.
 2013
 42 4P2 p. 760-761
2 p.
 artikel
75 Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan Furuta, S.
 2013
 42 4P2 p. 733-
1 p.
 artikel
76 Comparison of PR3-specific ANCA assays performance for diagnosis of granulomatosis with polyangiitis (GPA) Radice, A.
 2013
 42 4P2 p. 684-
1 p.
 artikel
77 Complement pathways activation in pauci-immune necrotizing glomerulonephritis with ANCA Figuères, M.L.
 2013
 42 4P2 p. 659-
1 p.
 artikel
78 Computer-aided immunofluorescence microscopy (CAIFM) for ANCA diagnostics Hochstrate, N.
 2013
 42 4P2 p. 685-
1 p.
 artikel
79 Computerized interstitial fibrosis quantification is the most powerful histological predictor of renal outcome in ANCA-associated vasculitis Levi, C.
 2013
 42 4P2 p. 667-
1 p.
 artikel
80 Contribution of anti-ferritin antibodies to the diagnosis of giant cell arteritis Regent, A.
 2013
 42 4P2 p. 730-731
2 p.
 artikel
81 Copy number variations of FCGR3B in eosinophilic granulomatosis with polyangiitis (Churg-Strauss) Bonatti, F.
 2013
 42 4P2 p. 696-
1 p.
 artikel
82 Co-trimoxazole monotherapy as induction therapy for localized granulomatosis with polyangiitis Tuin, J.
 2013
 42 4P2 p. 771-
1 p.
 artikel
83 Cutaneous hypersensitivity vasculitis associated with visceral Mycobacterium tuberculosis infection: A report of three cases Areses, M.
 2013
 42 4P2 p. 765-
1 p.
 artikel
84 Cutaneous vasculitis: Report of 117 cases Fanlo, P.
 2013
 42 4P2 p. 677-
1 p.
 artikel
85 Cyclophosphamide effect on immunoglobulins levels in AAV patients treated with long-term pre-emptive rituximab maintenance Besada, E.
 2013
 42 4P2 p. 767-768
2 p.
 artikel
86 Diffuse alveolar haemorrhage (DAH) in levamisole-adultered cocaine abuser resolved by rFVIIa infusion Pecci, E.
 2013
 42 4P2 p. 671-672
2 p.
 artikel
87 Distinct eicosanoid profile in exhaled breath condensates from granulomatosis with polyangiitis (Wegener's) patients Szczeklik, W.
 2013
 42 4P2 p. 709-
1 p.
 artikel
88 DNA from neutrophil extracellular traps is hypomethylated Hurtado, E.
 2013
 42 4P2 p. 759-
1 p.
 artikel
89 Dutch transplantation in vasculitis (DUTRAVAS)-study: Update on the outcome of renal transplantation in ANCA-associated vasculitis (AAV) patients in the Netherlands Göçeroğlu, A.
 2013
 42 4P2 p. 658-659
2 p.
 artikel
90 Efficacy of long-term treatment with TNF inhibitors in patients with refractory Takayasu arteritis Novikov, P.
 2013
 42 4P2 p. 723-
1 p.
 artikel
91 ENT involvement is related to better renal function in patients with ANCA-associated vasculitis Rahmattulla, C.
 2013
 42 4P2 p. 662-663
2 p.
 artikel
92 Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA), polyarteritis nodosa (PAN) and microscopic polyangiitis (MPA) with no initial Five-Factor Score-defined poor-prognosis factors (FFS=0): Baseline factors associated with cytotoxic agent and immunomodulator prescription Samson, M.
 2013
 42 4P2 p. 666-
1 p.
 artikel
93 Eosinophilic granulomatosis with polyangitis (EGPA): Clinical and immunologic expression in a single center cohort Baldini, C.
 2013
 42 4P2 p. 701-
1 p.
 artikel
94 Epidemiologic study of primary systemic vasculitides in adults in Southeastern Spain (Costa del Sol Occidental region, Málaga) Romero-Gómez, C.
 2013
 42 4P2 p. 705-
1 p.
 artikel
95 Epitope analysis of anti-myeloperoxidase antibodies in patients with ANCA-associated vasculitis Gou, S.J.
 2013
 42 4P2 p. 756-
1 p.
 artikel
96 Epitope analysis of anti-myeloperoxidase antibodies in propylthiouracil-induced ANCA-associated vasculitis Wang, C.
 2013
 42 4P2 p. 758-
1 p.
 artikel
97 Estimating renal survival using the ANCA-associated glomerulonephritis classification: A validation study Wilde, B.
 2013
 42 4P2 p. 747-748
2 p.
 artikel
98 Factors associated with long-term damage in the ANCA-associated vasculitides: An analysis of cohorts from the European vasculitis study group (EUVAS) therapeutic trials Robson, J.
 2013
 42 4P2 p. 745-
1 p.
 artikel
99 Factors associated with major cardiovascular events in patients with primary systemic necrotizing vasculitides: Results of a longitudinal long-term follow-up study Terrier, B.
 2013
 42 4P2 p. 674-675
2 p.
 artikel
100 Factors predictive of prognosis in renal AAV – A study of 104 patients in a single UK centre Tanna, A.
 2013
 42 4P2 p. 670-671
2 p.
 artikel
101 Fixed-interval repeat dose rituximab improves abnormalities in the periperhal B cell compartment and reduces relapse rates in ANCA associated vasculitis Wallin, E.
 2013
 42 4P2 p. 772-
1 p.
 artikel
102 Focal necrotizing and crescentic glomerulonephritis in patients with normal serum creatinine Mcadoo, S.P.
 2013
 42 4P2 p. 753-
1 p.
 artikel
103 Functionally effect regulatory B cells in patients with active ANCA vasculitis Aybar, L.
 2013
 42 4P2 p. 763-
1 p.
 artikel
104 Galactosylation and sialylation of anti-proteinase 3 antibodies in granulomatosis with polyangiitis is associated with increased inflammatory cytokines Morgan, M.
 2013
 42 4P2 p. 761-
1 p.
 artikel
105 Genetic regulation of CD177 – A receptor presenting anti-neutrophil cytoplasmic antigen proteinase 3 Eulenberg, C.
 2013
 42 4P2 p. 669-
1 p.
 artikel
106 Gestational rituximab exposure in women with vasculitis Pendergraft, W.
 2013
 42 4P2 p. 776-777
2 p.
 artikel
107 GPA and MPA patients have different serum cytokine profiles Avik, A.
 2013
 42 4P2 p. 712-
1 p.
 artikel
108 Granulomatosis with polyangiitis (Wegener's) is associated with HLA-DPB1*04 and EMA6A gene variants. Evidence from a genome-wide analysis Xie, G.
 2013
 42 4P2 p. 668-
1 p.
 artikel
109 Hemorrhagic emergency due to intrahepatic aneurism rupture in a patient with Polyateritis Nodosa after long time of episodic fever: A case report Silva, F.
 2013
 42 4P2 p. 743-744
2 p.
 artikel
110 High genetic diversity in nasal Staphylococcus aureus isolates from Granulomatosis with Polyangiitis (GPA) patients Van Timmeren, M.M.
 2013
 42 4P2 p. 655-
1 p.
 artikel
111 HMGB1 in ANCA-associated vasculitis: A longitudinal study Souza, A.W. Silva De
 2013
 42 4P2 p. 763-
1 p.
 artikel
112 Identification of target antigens of anti-endothelial cell antibodies in patients with ANCA-associated systemic vasculitis: A proteomic approach Régent, A.
 2013
 42 4P2 p. 651-652
2 p.
 artikel
113 IgA associated vasculitis (IgAV) – a 5-year retrospective study Gota, C.
 2013
 42 4P2 p. 741-742
2 p.
 artikel
114 IgG4 in chronic periaortitis Oliva, E.
 2013
 42 4P2 p. 729-
1 p.
 artikel
115 Illness perceptions and fatigue in systemic vasculitis Grayson, P.
 2013
 42 4P2 p. 737-738
2 p.
 artikel
116 IL-10 producing regulatory B-cells are diminished in ANCA-associated vasculitis Wilde, B.
 2013
 42 4P2 p. 758-759
2 p.
 artikel
117 Immunization of NOD mice with recombinant mouse proteinase 3 causes immune complex not pauci-immune crescentic glomerulonephritis Hu, P.
 2013
 42 4P2 p. 689-690
2 p.
 artikel
118 Immunopathology of active and remitting granulomatosis with poyangiitis (Wegener's) Rani, L.
 2013
 42 4P2 p. 714-715
2 p.
 artikel
119 Impaired endothelial function in patients with Takayasu's arteritis Alibaz-Oner, F.
 2013
 42 4P2 p. 717-718
2 p.
 artikel
120 Impairment in aortic elastic properties and mechanics of carotid artery system in patients with Takayasu's arteritis Alibaz-Oner, F.
 2013
 42 4P2 p. 718-
1 p.
 artikel
121 Implication of vascular endothelial cell-reactive invariant NKT cells in pathogenesis of small vessel vasculitis in rats Ishizu, A.
 2013
 42 4P2 p. 687-
1 p.
 artikel
122 Improving the quality and safety of intravenous cyclophosphamide (IV CYC): A regional audit of a best-practice protocol Rees, F.
 2013
 42 4P2 p. 769-
1 p.
 artikel
123 Incidence of coronary aneurysms in children with Kawasaki disease after early treatment with IVIG and aspirin: Report of 55 cases Romero, C.
 2013
 42 4P2 p. 771-
1 p.
 artikel
124 Incidence of granulomatosis with polyangiitis (Wegener's) among Greenlanders Faurschou, M.
 2013
 42 4P2 p. 703-
1 p.
 artikel
125 Incidence of PR3- and MPO-ANCA autoantibody specificity changes in ANCA associated vasculitis Holding, S.
 2013
 42 4P2 p. 683-
1 p.
 artikel
126 Increased migration and proliferation potential characterized vascular smooth muscle cells from patients with giant cell arteritis Regent, A.
 2013
 42 4P2 p. 731-
1 p.
 artikel
127 Index auteurs 2013
 42 4P2 p. 782-790
9 p.
 artikel
128 Induction treatment of ANCA associated vasculitis with a single dose of rituximab Little, M.
 2013
 42 4P2 p. 773-
1 p.
 artikel
129 Infection risk in ANCA-associated vasculitis Morgan, M.
 2013
 42 4P2 p. 665-666
2 p.
 artikel
130 Infectious complications related to treatment in an inception cohort of antineutrophil cytoplasmic antibody associated vasculitis Mcgregor, J.
 2013
 42 4P2 p. 767-
1 p.
 artikel
131 Infliximab for Behçet disease with aortic involvement Okada, M.
 2013
 42 4P2 p. 690-
1 p.
 artikel
132 Infliximab treatment of resistant uveitis in Behçet disease Becvar, R.
 2013
 42 4P2 p. 690-
1 p.
 artikel
133 Initial presentation of giant cell arteritis with ischemic optic neuropathy without headache: Report of four cases Duro, V.
 2013
 42 4P2 p. 724-
1 p.
 artikel
134 14-3-3 in large vessel vasculitis: A novel antigen Chakravarti, R.
 2013
 42 4P2 p. 720-
1 p.
 artikel
135 Interleukin-21, B cell activating factor and unmethylated CpG oligodeoxynucleotides synergize in promoting anti-Proteinase 3 autoantibody production in vitro Lepse, N.
 2013
 42 4P2 p. 759-
1 p.
 artikel
136 Interleukin 15, CD56+ T-cells and ANCA-associated vasculitis (AAV) Buhl, B.M.
 2013
 42 4P2 p. 713-
1 p.
 artikel
137 Inter-observer reproducibility of two CT scan staging systems to evaluate sinonasal involvement in granulomatosis with polyangiitis (Wegener's) Díaz, P.
 2013
 42 4P2 p. 711-
1 p.
 artikel
138 Investigating Annexin-A1 in ANCA vasculitis and glomerulonephritis Jukes, P.
 2013
 42 4P2 p. 689-
1 p.
 artikel
139 Investigating the microRNA signature of ANCA associated vasculitis Brown, N.
 2013
 42 4P2 p. 756-757
2 p.
 artikel
140 In vitro neutrophil activation by ANCA from patients with ANCA associated vasculitis; degranulation and oxidative burst Ohlsson, S.
 2013
 42 4P2 p. 764-
1 p.
 artikel
141 ITAS.A suggests persistent disease activity in Takayasu aorto-arteritis after 6 months induction therapy Bacon, P.
 2013
 42 4P2 p. 719-
1 p.
 artikel
142 ITAS.A suggests persistent disease activity in Takayasu aorto-arteritis (TA) after induction therapy Misra, R.
 2013
 42 4P2 p. 729-730
2 p.
 artikel
143 Lack of efficacy of tocilizumab in mucocutaneous Behçet's syndrome: Report of two cases Diamantopoulos, A.P.
 2013
 42 4P2 p. 769-
1 p.
 artikel
144 Lactoferrin inhibits formation of neutrophil extracellular traps in inflammation Okubo, K.
 2013
 42 4P2 p. 770-
1 p.
 artikel
145 L31. A GWAS in ANCA-associated vasculitis: Will genetics help re-define clinical classification? Lyons, Paul A.
 2013
 42 4P2 p. 589-591
3 p.
 artikel
146 LAMP-2, a potential novel receptor on human monocytes derived dendritic cells (MDDC) Leone, D.L.
 2013
 42 4P2 p. 761-762
2 p.
 artikel
147 L32. ANCA vasculitis over the world. What do we learn from country differences? Watts, Richard A.
 2013
 42 4P2 p. 591-593
3 p.
 artikel
148 L10. Animal models of ANCA-associated vasculitis: Effector mechanisms and experimental therapies Schreiber, Adrian
 2013
 42 4P2 p. 520-523
4 p.
 artikel
149 L8. Animal models of ANCA associated vasculitis: The contribution of autoantibodies and autoreactive T cells Heeringa, Peter
 2013
 42 4P2 p. 515-517
3 p.
 artikel
150 L7. Animal models of PR3-ANCA vasculitis: Approaches and controversies Little, Mark A.
 2013
 42 4P2 p. 512-515
4 p.
 artikel
151 L27. Antibodies versus phenotypes: A clinician's view Jayne, David
 2013
 42 4P2 p. 579-582
4 p.
 artikel
152 L45. Aortitis, retroperitoneal fibrosis, and IgG4-related disease Stone, John H.
 2013
 42 4P2 p. 622-625
4 p.
 artikel
153 L13. Apoptosis, Apoptotic cell clearance and resolution of inflammation Rossi, Adriano G.
 2013
 42 4P2 p. 536-537
2 p.
 artikel
154 L3. Are mononuclear cells predominant actors of endothelial damage in vasculitis? Abdulahad, Wayel H.
 2013
 42 4P2 p. 499-503
5 p.
 artikel
155 Large vessel giant cell arteritis: Clinical, imaging characteristics and outcomes Kermani, T.
 2013
 42 4P2 p. 722-723
2 p.
 artikel
156 Large vessel vasculitis: Estimating disease activity in patients with thoracic aortic aneurysms Clifford, A.
 2013
 42 4P2 p. 673-
1 p.
 artikel
157 L30. Assessment of vasculitis extent and severity Pipitone, Nicolò
 2013
 42 4P2 p. 588-589
2 p.
 artikel
158 L22. Crescent formation: Unraveling local mediators that break glomerular epithelial cell tolerance to immune injury Hénique, Carole
 2013
 42 4P2 p. 565-568
4 p.
 artikel
159 Leflunomide as a corticosteroid-sparing agent in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR): A consecutive case series Hetland, H.
 2013
 42 4P2 p. 726-727
2 p.
 artikel
160 L5. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) Cordier, Jean-François
 2013
 42 4P2 p. 507-510
4 p.
 artikel
161 L6. Eosinophilic granulomatosis with polyangiitis: Future therapies Moosig, Frank
 2013
 42 4P2 p. 510-512
3 p.
 artikel
162 L4. Eosinophils: How they contribute to endothelial damage and dysfunction Roufosse, Florence
 2013
 42 4P2 p. 503-507
5 p.
 artikel
163 L15. EULAR/ACR 2012 classification criteria for polymyalgia rheumatica Matteson, Eric L.
 2013
 42 4P2 p. 543-546
4 p.
 artikel
164 L36. Evidence-based clinical science and art in the diagnosis of central nervous system vasculitis Calabrese, Leonard H.
 2013
 42 4P2 p. 600-602
3 p.
 artikel
165 L35. Fc receptors and cell activation Monteiro, Renato C.
 2013
 42 4P2 p. 598-599
2 p.
 artikel
166 L51. From immunosuppression to selective treatments: The benefit–risk ratio Guillevin, Loïc
 2013
 42 4P2 p. 641-643
3 p.
 artikel
167 L39. Fulminant anca vasculitis Karras, Alexandre
 2013
 42 4P2 p. 607-609
3 p.
 artikel
168 L18. Granuloma formation in granulomatosis with polyangiitis Holl-Ulrich, Konstanze
 2013
 42 4P2 p. 555-558
4 p.
 artikel
169 L11. Hepatitis C virus mixed cryoglobulinemia vasculitis: Therapeutic options Cacoub, Patrice
 2013
 42 4P2 p. 523-527
5 p.
 artikel
170 L26. How antigens influence the disease: An immunologist point of view Free, Meghan E.
 2013
 42 4P2 p. 577-579
3 p.
 artikel
171 L38. How to treat primary vasculitis of the central nervous system Pagnoux, Christian
 2013
 42 4P2 p. 605-607
3 p.
 artikel
172 Limited otological eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) – a new disease subset Der Kureghian, J.
 2013
 42 4P2 p. 699-
1 p.
 artikel
173 L14. Immunomodulatory properties of apoptotic cells Perruche, Sylvain
 2013
 42 4P2 p. 537-543
7 p.
 artikel
174 L21. Kidneys in ANCA-associated vasculitis: What to learn from biopsies? Rahmattulla, Chinar
 2013
 42 4P2 p. 563-565
3 p.
 artikel
175 L24. Local treatments of subglottic and tracheal stenoses in granulomatosis with polyangiitis (Wegener's) Rasmussen, Niels
 2013
 42 4P2 p. 571-574
4 p.
 artikel
176 L19. Lymphoid neogenesis in vascular chronic inflammation Nicoletti, Antonino
 2013
 42 4P2 p. 558-560
3 p.
 artikel
177 L44. Management of relapses in vasculitis Mouthon, Luc
 2013
 42 4P2 p. 619-622
4 p.
 artikel
178 L25. Medical treatment of subglottic stenosis in granulomatosis with polyangiitis (Wegener's) Monach, Paul A.
 2013
 42 4P2 p. 575-576
2 p.
 artikel
179 L20. Memory T-cells in vasculitis Lamprecht, Peter
 2013
 42 4P2 p. 560-563
4 p.
 artikel
180 L42. Morbidity in patients with ANCA-associated vasculitis Harper, Lorraine
 2013
 42 4P2 p. 612-616
5 p.
 artikel
181 L33. Neutrophil in immunity: A key modulator Cassatella, Marco A.
 2013
 42 4P2 p. 594-595
2 p.
 artikel
182 L34. Neutrophils in ANCA-associated vasculitis: Still under investigation Witko-Sarsat, Véronique
 2013
 42 4P2 p. 595-597
3 p.
 artikel
183 L2. Neutrophil transmigration in vivo: Mechanisms, dynamics and contribution to dissemination of systemic inflammation Nourshargh, Sussan
 2013
 42 4P2 p. 498-499
2 p.
 artikel
184 L46. Novel forms of clinical vasculitis: Anti-GBM vasculitis (Goodpasture's disease) McAdoo, Stephen P.
 2013
 42 4P2 p. 625-628
4 p.
 artikel
185 Longitudinal ANCA measurements for predicting a relapse are useful in patients with severe disease but not in patients with limited disease Kemna, M.
 2013
 42 4P2 p. 754-
1 p.
 artikel
186 Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in Granulomatosis with Polyangiitis: Results from a single centre Besada, E.
 2013
 42 4P2 p. 777-
1 p.
 artikel
187 Long-term follow-up of 96 GPA patients at a single centre Rees, F.
 2013
 42 4P2 p. 708-
1 p.
 artikel
188 Long term follow up of patients who received repeat dose rituximab as maintenance therapy for ANCA associated vasculitis (AAV) Smith, R.
 2013
 42 4P2 p. 775-776
2 p.
 artikel
189 Long-term outcome in patients with both ANCA and GBM positivity Tanna, A.
 2013
 42 4P2 p. 667-668
2 p.
 artikel
190 Long-term outcome of GPA and MPA in a population based cohort Watts, R.A.
 2013
 42 4P2 p. 746-
1 p.
 artikel
191 Long-term outcome of low dose cyclophosphamide (CYC) and plasma exchange (PLEX) induction in ANCA-associated vasculitis (AAV) Szpirt, W.
 2013
 42 4P2 p. 754-
1 p.
 artikel
192 Long-term outcome of 123 microscopic polyangiitis patients in a monocentric German cohort Schinke, S.
 2013
 42 4P2 p. 732-
1 p.
 artikel
193 Long-term outcome of severe alveolar hemorrhage in ANCA-associated vasculitis: A retrospective cohort study Hruskova, Z.
 2013
 42 4P2 p. 752-
1 p.
 artikel
194 Long-term outcomes of patients with Reversible Cerebral Vasoconstriction Syndrome (RCVS) John, S.
 2013
 42 4P2 p. 744-
1 p.
 artikel
195 Long-term outcomes of patients with reversible cerebral vasoconstriction syndrome (RCVS) Hajj-Ali, R.
 2013
 42 4P2 p. 670-
1 p.
 artikel
196 Low %CD5+ B cells in patients with ANCA vasculitis portends a shorter time to relapse after rituximab Bunch, D.
 2013
 42 4P2 p. 754-755
2 p.
 artikel
197 L1. Pathogenesis of ANCA-associated vasculitis: Observations, theories and speculations Charles Jennette, J.
 2013
 42 4P2 p. 493-498
6 p.
 artikel
198 L49. Percutaneous interventions in Takayasu arteritis Joseph, George
 2013
 42 4P2 p. 635-637
3 p.
 artikel
199 L41. Perspectives on the treatment of giant cell arteritis Langford, Carol A.
 2013
 42 4P2 p. 609-612
4 p.
 artikel
200 L29. Relevance of anti-LAMP-2 in vasculitis: Why the controversy Kain, Renate
 2013
 42 4P2 p. 584-588
5 p.
 artikel
201 L28. Relevance of detection techniques for ANCA testing Elena, Csernok
 2013
 42 4P2 p. 582-584
3 p.
 artikel
202 L23. Renal transplantation in ANCA-associated vasculitis Segelmark, Mårten
 2013
 42 4P2 p. 568-571
4 p.
 artikel
203 L37. Reversible cerebral vasoconstriction syndrome: Distinction from CNS vasculitis Ducros, Anne
 2013
 42 4P2 p. 602-604
3 p.
 artikel
204 L12. Rheumatoid arthritis vasculitis Puéchal, Xavier
 2013
 42 4P2 p. 527-530
4 p.
 artikel
205 L43. Seropositive and negative ANCA-associated vasculitis, anti-MPO and PR3-vasculitis: Different outcomes? Holle, Julia U.
 2013
 42 4P2 p. 616-619
4 p.
 artikel
206 L47. Single-organ vasculitis: Conceptual and practical considerations Mahr, Alfred
 2013
 42 4P2 p. 628-634
7 p.
 artikel
207 L48. The challenges in assessing Takayasu arteritis Bacon, Paul
 2013
 42 4P2 p. 634-635
2 p.
 artikel
208 L50. The future of international clinical trials in vasculitis Merkel, Peter A.
 2013
 42 4P2 p. 637-641
5 p.
 artikel
209 L9. The role of genetic background in an animal model of ANCA-associated vasculitis Xiao, Hong
 2013
 42 4P2 p. 517-520
4 p.
 artikel
210 L16. The specificities of pediatric vasculitis classification Yildiz, Cigdem
 2013
 42 4P2 p. 546-550
5 p.
 artikel
211 L52. Vasculitis treatment: Is it time to change the standard of care for ANCA-associated vasculitis? Hoffman, Gary S.
 2013
 42 4P2 p. 643-650
8 p.
 artikel
212 L17. What can we expect from the revised Chapel Hill consensus conference nomenclature of vasculitis? Jennette, J. Charles
 2013
 42 4P2 p. 550-555
6 p.
 artikel
213 Macrophage activation syndrome in vasculitis: An underrecognised complication? Damian, L.
 2013
 42 4P2 p. 742-
1 p.
 artikel
214 Maintenance therapy using rituximab-induced continuous B cell depletion for ANCA vasculitis Pendergraft, W.
 2013
 42 4P2 p. 774-775
2 p.
 artikel
215 Maintenance treatment in childhood granulomatosis with polyangiitis Twilt, M.
 2013
 42 4P2 p. 712-
1 p.
 artikel
216 Many faces of cutaneous vasculitis in eosinophilic granulomatosis with polyangiitis: An excellent model for histopathology of cutaneous vasculitis Chen, K.R.
 2013
 42 4P2 p. 695-
1 p.
 artikel
217 Markers for work disability in ANCA-associated vasculitis Basu, N.
 2013
 42 4P2 p. 745-746
2 p.
 artikel
218 Methotrexate plus prednisone in patients with relapsing chronic periaortitis Alberici, F.
 2013
 42 4P2 p. 720-721
2 p.
 artikel
219 Methotrexate vs cyclophosphamide as maintenance therapy in severe eosinophilic granulomatosis with polyangitiis (Churg Strauss): A subanalysis of the powercime trial Maritati, F.
 2013
 42 4P2 p. 696-697
2 p.
 artikel
220 Microscopic polyangiitis in the setting of usual interstitial pneumonia Keogh, K.
 2013
 42 4P2 p. 703-
1 p.
 artikel
221 Microscopic vasculitis associated to Sjögren's syndrome. About 4 cases Ben Ghorbel, I.
 2013
 42 4P2 p. 766-
1 p.
 artikel
222 Monocyte chemoattractant protein-1 (MCP-1) in antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis: Biomarker potential and association with polymorphisms in the MCP-1 and the CC chemokine receptor-2 (CCR2) gene Jönsson, N.
 2013
 42 4P2 p. 755-
1 p.
 artikel
223 Multi-center evaluation of a novel chemiluminescent rapid assay for the detection of PR3-ANCA Mahler, M.
 2013
 42 4P2 p. 683-684
2 p.
 artikel
224 Multiple infections in a Filipino with polyangiitis overlap syndrome (POS) Racaza, G.
 2013
 42 4P2 p. 707-
1 p.
 artikel
225 Nasal mucosa provides a niche for autoreactive plasma cells in granulomatosis with polyangiitis (Wegener's) Voswinkel, J.
 2013
 42 4P2 p. 658-
1 p.
 artikel
226 Neutrophils in ANCA vasculitis – old and apathetic Hellmark, T.
 2013
 42 4P2 p. 655-656
2 p.
 artikel
227 Normal frequencies of circulating Th1 and Th17 cells in GCA patients Van Der Geest, K.
 2013
 42 4P2 p. 724-
1 p.
 artikel
228 Occupational and environmental risk factors in chronic periaortitis: A case-control study Urban, M.L.
 2013
 42 4P2 p. 675-676
2 p.
 artikel
229 Orthotopic heart transplantation in eosinophilic granulomatosis with polyangiitis Groh, M.
 2013
 42 4P2 p. 652-653
2 p.
 artikel
230 Outcome and prognostic factors in elderly patients with ANCA-associated vasculitis Weiner, M.
 2013
 42 4P2 p. 674-
1 p.
 artikel
231 Outcome of neuro-Behçet: Analysis of a large cohort Noel, N.
 2013
 42 4P2 p. 692-
1 p.
 artikel
232 Outcome of 1516 percutaneous interventions in 401 patients with Takayasu arteritis – a single-center experience from South India Joseph, G.
 2013
 42 4P2 p. 721-
1 p.
 artikel
233 Outcome of vascular interventions in Takayasu arteritis Rajappa, M.
 2013
 42 4P2 p. 720-
1 p.
 artikel
234 Outcomes in patients with granulomatosis with polyangiitis (Wegener's) treated with short vs. long-term maintenance therapy Springer, J.
 2013
 42 4P2 p. 675-
1 p.
 artikel
235 Pandemic influenza vaccine in granulomatosis with polyangiitis: Adequate humoral response and safety in inactive patients Aikawa, N.E.
 2013
 42 4P2 p. 706-
1 p.
 artikel
236 Pathogenesis of atherosclerosis in granulomatosis with polyangiitis Hajj-Ali, R.
 2013
 42 4P2 p. 711-
1 p.
 artikel
237 Pathogenic leukocytosis and their susceptibility QTLs for vasculitis and crescentic glomerulonephritis in a model of SCG/Kj mice Yoshitomo, H.
 2013
 42 4P2 p. 687-
1 p.
 artikel
238 Patient reported outcomes in ANCA-associated vasculitis. A prospective comparison between BVAS and RAPID3 on an MDHAQ Sreih,
 2013
 42 4P2 p. 749-
1 p.
 artikel
239 Patients positive for both MPO-ANCA and PR3-ANCA do not present idiopathic systemic necrotizing vasculitis Chevailler, A.
 2013
 42 4P2 p. 685-686
2 p.
 artikel
240 Patients with Takayasu's arteritis having persistent acute phase response usually have an increased major vessel uptake by 18F-FDG-PET Alibaz-Oner, F.
 2013
 42 4P2 p. 722-
1 p.
 artikel
241 Pattern of renal involvement and its correlation with outcomes in patients with small and medium vessel vasculitis – experience from a tertiary care center in India Sharma, A.
 2013
 42 4P2 p. 705-706
2 p.
 artikel
242 Pentraxin-3 and soluble tumor necrosis factor-like weak inducer of apoptosis (s-Tweak) in anti-neutrophil antibody associated vasculitis (AAV) Wendt, M.
 2013
 42 4P2 p. 758-
1 p.
 artikel
243 Performance of the ACR classification criteria as diagnostic criteria for granulomatosis with polyangiitis (GPA) (Wegener's) in a respiratory referral centre Contreras-Rodríguez, F.
 2013
 42 4P2 p. 657-
1 p.
 artikel
244 Phagocytosis of apoptotic cells expressing PR3 impaired macrophage anti-inflammatory reprogramming Millet, A.
 2013
 42 4P2 p. 656-
1 p.
 artikel
245 Pituitary dysfunction in granulomatosis with polyangiitis Cartin-Ceba, R.
 2013
 42 4P2 p. 710-711
2 p.
 artikel
246 Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis: A randomized controlled trial. PEXIVAS Brezina, B.
 2013
 42 4P2 p. 772-
1 p.
 artikel
247 Positron emission tomography scanning in ANCA associated vasculitis Kemna, M.
 2013
 42 4P2 p. 742-
1 p.
 artikel
248 Potential defect in annexin-A1-dependent anti-inflammatory mechanisms in GPA: Its cleavage by PR3 and its inhibition by autoantibodies Pederzoli-Ribeil, M.
 2013
 42 4P2 p. 764-
1 p.
 artikel
249 PR3-ANCA: A promising biomarker for the differentiation of ulcerative colitis and Crohn's disease Mahler, M.
 2013
 42 4P2 p. 684-
1 p.
 artikel
250 Predicting relapse in granulomatosis with polyangiitis: The role of biomarkers Hogan, P.
 2013
 42 4P2 p. 716-
1 p.
 artikel
251 Predicting renal relapse with the histopathologic classification of ANCA-associated glomerulonephritis Göçeroğlu, A.
 2013
 42 4P2 p. 750-751
2 p.
 artikel
252 Prediction of outcome of treatment by gene expression profiling of peripheral blood in patients with microscopic polyangiitis Ishizu, A.
 2013
 42 4P2 p. 733-
1 p.
 artikel
253 Predictors of early relapse in patients with non-infectious mixed cryoglobulinemia vasculitis: Results from the French nationwide CryoVas survey Terrier, B.
 2013
 42 4P2 p. 693-
1 p.
 artikel
254 Predictors of treatment resistance and relapse in Chinese patients with antineutrophil cytoplasmic antibody-associated disease Cao, Y.
 2013
 42 4P2 p. 772-773
2 p.
 artikel
255 Premature ovarian failure in women with ANCA-associated vasculitis Tuin, J.
 2013
 42 4P2 p. 665-
1 p.
 artikel
256 Presence of fibromyalgia and fatigue is not increased in patients with Takayasu's arteritis Alibaz-Oner, F.
 2013
 42 4P2 p. 717-
1 p.
 artikel
257 Presentation and management of granulomatosis with polyangiitis (Wegener's) (GPA) central nervous system (CNS) involvement De Luna, G.
 2013
 42 4P2 p. 710-
1 p.
 artikel
258 Prevalence of anti-neutrophil cytoplasmic antibodies in infective endocarditis: An analysis of 109 cases Mahr, A.
 2013
 42 4P2 p. 663-664
2 p.
 artikel
259 Prognosis of patients with ANCA-associated glomerulonephritis (GN) presenting with severe renal failure Lee, T.
 2013
 42 4P2 p. 671-
1 p.
 artikel
260 Proposal of an algorithm for the diagnosis and aetiologic identification of diffuse alveolar haemorrhage (DAH) Ramírez-Assad, C.
 2013
 42 4P2 p. 737-
1 p.
 artikel
261 Proteinase 3induces shape change in platelets through activation of the Rho/Rho-kinase signaling pathway Peng, X.
 2013
 42 4P2 p. 651-
1 p.
 artikel
262 Proteinase 3 (PR3) is a phosphatidylserine-binding protein that can bind microparticles: Relevance in the context of granulomatosis with polyangiitis (GPA) Pederzoli-Ribeil, M.
 2013
 42 4P2 p. 652-
1 p.
 artikel
263 Proteinase 3 reactive T cells in patients with granulomatosis with polyangiitis Scollard, S.
 2013
 42 4P2 p. 716-
1 p.
 artikel
264 Quantifying the effect of rituximab on changes in serum immunoglobulin G Roberts, D.
 2013
 42 4P2 p. 766-767
2 p.
 artikel
265 Radiological features in Takayasu’ arteritis in Tunisia. About 34 cases Belfeki, N.
 2013
 42 4P2 p. 731-732
2 p.
 artikel
266 Randomized clinical trial of extended versus standard azathioprine maintenance therapy in newly diagnosed PR3-ANCA positive vasculitis patients at high-risk for disease relapse De Joode, A.A.E.
 2013
 42 4P2 p. 680-
1 p.
 artikel
267 Rapid control of disease activity by Tocilizumab in ten “difficult-to-treat” cases of Takayasu arteritis Goel, R.
 2013
 42 4P2 p. 725-
1 p.
 artikel
268 Rapidly progressive glomerulonephritis is not the sole presentation of renal involvement in ANCA associated vasculitis Levi, C.
 2013
 42 4P2 p. 734-735
2 p.
 artikel
269 Reclassifying ANCA-associated vasculitis using the EUVAS algorithm: Epidemiology and survival from the NORVASC register Abdulkader, R.
 2013
 42 4P2 p. 661-662
2 p.
 artikel
270 Recognizing childhood inflammatory brain diseases in Canada Twilt, M.
 2013
 42 4P2 p. 670-
1 p.
 artikel
271 Recurrent acquired ANCA-positive agranulocytosis after cocaine exposure: A chronic disease? Schieppati, F.
 2013
 42 4P2 p. 664-
1 p.
 artikel
272 Referral causes and initial diagnosis of ANCA-associated vasculitides in a pulmonary tertiary centre. Retrospective study in 90 patients Flores-Suárez, L.F.
 2013
 42 4P2 p. 702-
1 p.
 artikel
273 Refractory cutaneous vasculitis associated with MAGIC syndrome: Case report Mellado, M.
 2013
 42 4P2 p. 691-
1 p.
 artikel
274 Renal histopathological classification of ANCA associated glomerulonephritis: A validation study of 92 patients De Sousa Amorim, E.
 2013
 42 4P2 p. 735-736
2 p.
 artikel
275 Resolution of proteinuria and hematuria in ANCA-associated nephritis Lilliebladh, S.
 2013
 42 4P2 p. 713-
1 p.
 artikel
276 Results of ANCA standardisation and their diagnostic usefulness in ANCA-associated vasculitides (AASV) in a respiratory referral centre in Mexico Contreras-Rodríguez, F.
 2013
 42 4P2 p. 682-683
2 p.
 artikel
277 Re-treatment with rituximab in ANCA-associated vasculitis only in the presence of clinical relapse: A single centre experience Jeannin, G.
 2013
 42 4P2 p. 776-
1 p.
 artikel
278 Retreatment with Rituximab in the RAVE Trial Miloslavsky, E.
 2013
 42 4P2 p. 778-
1 p.
 artikel
279 Retroperitoneal fibrosis at the onset of ANCA associated vasculitis: The risk of a delay in the diagnosis of vasculitis Possenti, S.
 2013
 42 4P2 p. 742-
1 p.
 artikel
280 Ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis/Peg-IFNa/ Saadoun, D.
 2013
 42 4P2 p. 694-695
2 p.
 artikel
281 Risk of cardiovascular disease early and late after a diagnosis of giant cell arteritis Tomasson, G.
 2013
 42 4P2 p. 673-
1 p.
 artikel
282 Risk of malignancy with long-term immunosuppression in ANCA-associated vasculitis Rahmattulla, C.
 2013
 42 4P2 p. 767-
1 p.
 artikel
283 Rituximab and vascular function in granulomatosis with polyangiitis (GPA) Casian, A.
 2013
 42 4P2 p. 738-739
2 p.
 artikel
284 Rituximab therapy for granulomatous poliangeitis (Wegener's granulomatosis) with refractory granulomatous manifestations Solans, R.
 2013
 42 4P2 p. 660-
1 p.
 artikel
285 Rituximab use in patients with ANCA-associated vasculitis: Clinical efficacy and impact on immunological parameters Chocova, Z.
 2013
 42 4P2 p. 774-
1 p.
 artikel
286 Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. A prospective study in 117 patients Guillevin, L.
 2013
 42 4P2 p. 679-
1 p.
 artikel
287 Rituximab versus azathioprine for maintenance in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (MAINRITSAN): Follow-up at 34 months Terrier, B.
 2013
 42 4P2 p. 778-779
2 p.
 artikel
288 Safety of remission induction with rituximab versus cyclophosphamide in patients 65 and older with severe ANCA-associated vasculitis Miloslavsky, E.
 2013
 42 4P2 p. 779-780
2 p.
 artikel
289 Serial chest high-resolution CT (HRCT) scans in patients with ANCA-associated vasculitis Konopasek, P.
 2013
 42 4P2 p. 739-
1 p.
 artikel
290 Serum biomarkers during relapsing disease in eosinophilic granulomatosis with polyangiitis Dejaco, C.
 2013
 42 4P2 p. 700-701
2 p.
 artikel
291 Serum biomarkers signature identifies patients with overt B-cell non-Hodgkin lymphoma associated with mixed cryoglobulinemia in chronic HCV infection Terrier, B.
 2013
 42 4P2 p. 654-
1 p.
 artikel
292 Serum C-reactive protein reflects the proportions of cellular crescent formation and glomerulosclerosis in patients with microscopic polyangiitis Iwakiri, T.
 2013
 42 4P2 p. 734-
1 p.
 artikel
293 Serum osteopontin in giant cell arteritis: A biomarker associated with sistemic inflammatory response and relapsing course Prieto-González, S.
 2013
 42 4P2 p. 723-
1 p.
 artikel
294 Severe diffuse alveolar haemorrhage after TAVI with CoreValve in patient with AAV and Horton disease in remission. An immuno-allergic reaction? Gregorini, G.A.
 2013
 42 4P2 p. 765-766
2 p.
 artikel
295 Severe fatigue and psychological morbidity in ANCA-associated vasculitis Mcclean, A.
 2013
 42 4P2 p. 749-750
2 p.
 artikel
296 Severe fatigue in ANCA-associated vasculitis is associated with altered perception and reduced cardiovascular fitness Mcclean, A.
 2013
 42 4P2 p. 750-
1 p.
 artikel
297 Severe relapse of Takaysu arteritis on ongoing treatment with tocilizumab Gunnarsson, R.
 2013
 42 4P2 p. 727-
1 p.
 artikel
298 Silica binds to LL-37 and CpG DNA complexes Hurtado, P.R.
 2013
 42 4P2 p. 741-
1 p.
 artikel
299 Single-organ gallbladder vasculitis: Characterization and distinction from systemic vasculitis involving the gallbladder. An analysis of 57 patients Hernández-Rodríguez, J.
 2013
 42 4P2 p. 740-
1 p.
 artikel
300 Sinonasal involvement in patients with eosinophilic granulomatosis with polyangitis (EGPA, ex Churg Strauss Syndrome): A modern look to an ancient problem Seccia, V.
 2013
 42 4P2 p. 701-
1 p.
 artikel
301 Spleen tyrosine kinase (SYK) inhibition in experimental autoimmune glomerulonephritis (EAG) Mcadoo, S.P.
 2013
 42 4P2 p. 653-654
2 p.
 artikel
302 S3. Rituximab for ANCA-associated vasculitides: The French experience Charles, Pierre
 2013
 42 4P2 p. 534-536
3 p.
 artikel
303 S1. Rituximab for ANCA-associated vasculitis: The experience in the United States Clain, Jeremy M.
 2013
 42 4P2 p. 530-532
3 p.
 artikel
304 S2. Rituximab for ANCA-associated vasculitis: The UK experience Jayne, David
 2013
 42 4P2 p. 532-534
3 p.
 artikel
305 Study of side effects of glucocorticoid treatment in 28 patients with giant cell arteritis (GCA) Huarte, E.
 2013
 42 4P2 p. 726-
1 p.
 artikel
306 Successful pregnancy in patients with granulomatosis with polyangiitis (Wegener's) after rituximab treatment Novikov, P.
 2013
 42 4P2 p. 709-
1 p.
 artikel
307 Successful treatment of refractory cutaneous ulcer associated with polyarteritis nodosa with bosentan Fanlo, P.
 2013
 42 4P2 p. 771-772
2 p.
 artikel
308 Successful treatment with rituximab in patients with Schnitzler syndrome Novikov, P.
 2013
 42 4P2 p. 738-
1 p.
 artikel
309 Synergistic effect of GCSF and LPS in ANCA Vasculitis Popat, R.
 2013
 42 4P2 p. 686-687
2 p.
 artikel
310 Systemic large vessel vasculitis pattern in chronic periaortitis: Identification of a new disease subset Palmisano, A.
 2013
 42 4P2 p. 728-
1 p.
 artikel
311 Takayasu arteritis – An outcome study in a UK cohort Youngstein, T.
 2013
 42 4P2 p. 677-
1 p.
 artikel
312 Takayasu arteritis in Tunisia: Clinical study of 34 cases Ben Ghorbel, I.
 2013
 42 4P2 p. 731-
1 p.
 artikel
313 Takayasu arteritis (TA) and sacroiliitis. A large vessels vasculitis masquerade from anti-TNF alpha therapy Toniati, P.
 2013
 42 4P2 p. 729-
1 p.
 artikel
314 Takayasu's arteritis in southern Sweden Mohammad, A.
 2013
 42 4P2 p. 719-
1 p.
 artikel
315 The association of granulomatosis with polyangiitis and IgG4-related disease: A case series Dudley, L.
 2013
 42 4P2 p. 706-707
2 p.
 artikel
316 The association of IgM ANCA with alveolar hemorrhage revisited Clain, J.
 2013
 42 4P2 p. 685-
1 p.
 artikel
317 The diagnostic value of distinguishing and reporting different perinuclear ANCA (P-ANCA) immunofluorescence patterns: A prospective study Perel, S.
 2013
 42 4P2 p. 681-
1 p.
 artikel
318 The ear, nose and throat manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) Der Kureghian, J.
 2013
 42 4P2 p. 699-
1 p.
 artikel
319 The higher response of pandemic influenza vaccination in Takayasu’arteritis: A prospectively controlled study Calich, A.L.
 2013
 42 4P2 p. 718-719
2 p.
 artikel
320 The informational needs of patients with ANCA-vasculitis – a multinational study Mooney, J.
 2013
 42 4P2 p. 736-737
2 p.
 artikel
321 The interaction between C5a and sphingosine-1-phosphate in neutrophils for ANCA-mediated activation Hao, J.
 2013
 42 4P2 p. 757-
1 p.
 artikel
322 The necessity of the addition of interstitial pathological parameters on the glomerular histological classification to predict the long-term outcome in MPO-ANCA-associated RPGN cohort in Japan Muso, E.
 2013
 42 4P2 p. 667-
1 p.
 artikel
323 The protective role of NADPH oxidase in ANCA-induced vasculitis Schreiber, A.
 2013
 42 4P2 p. 688-689
2 p.
 artikel
324 Therapeutic drug monitoring detects high interpatient variability in response to mycophenolic acid treatment in patients with ANCA-associated vasculitis Schaier, M.
 2013
 42 4P2 p. 773-774
2 p.
 artikel
325 The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK Robson, J.
 2013
 42 4P2 p. 672-673
2 p.
 artikel
326 The role of MPO-positive cells and MPO deposition in glomerular capillary injury in patients with various glomerulonephritis Kawashima, S.
 2013
 42 4P2 p. 732-733
2 p.
 artikel
327 The role of quantitative trait loci (QTL) in the pathogenesis of experimental autoimmune vasculitis (EAV) Mcdaid, J.P.
 2013
 42 4P2 p. 688-
1 p.
 artikel
328 The unmet need in Behçet's disease: Most patients are not in complete remission in the long-term follow-up Alibaz-Oner, F.
 2013
 42 4P2 p. 676-677
2 p.
 artikel
329 The value of a patient global assessment for disease activity in granulomatosis with polyangiitis Tomasson, G.
 2013
 42 4P2 p. 749-
1 p.
 artikel
330 Thrombotic vasculopathy with neovascularisation associated with probably levamisole-contaminated cocaine: Report of 2 cases Flores-Suárez, L.F.
 2013
 42 4P2 p. 764-765
2 p.
 artikel
331 Time to remission and relapse following rituximab in an inception cohort of antineutrophil cytoplasmic antibody associated vasculitis Studstill, M.E.
 2013
 42 4P2 p. 774-
1 p.
 artikel
332 Tissue destruction in granulomatosis with polyangiitis: Common histological pattern in mice and men Kesel, N.
 2013
 42 4P2 p. 760-
1 p.
 artikel
333 Tocilizumab for the treatment of giant cell arteritis: Extended follow-up Unizony, S.
 2013
 42 4P2 p. 727-
1 p.
 artikel
334 Tocilizumab in refractory Takayasu arteritis: Case series and literature review Abisror, N.
 2013
 42 4P2 p. 725-726
2 p.
 artikel
335 Towards an international standardized ENT disease activity score in GPA Martinez Del Pero, M.
 2013
 42 4P2 p. 748-
1 p.
 artikel
336 Tracheal and bronchial stenoses in granulomatosis with polyangiitis (Wegener) (GPA) Terrier, B.
 2013
 42 4P2 p. 659-660
2 p.
 artikel
337 Tracheobronchial stenoses (TBS) in granulomatosis with polyangiitis (Wegener) (GPA) Girard, C.
 2013
 42 4P2 p. 715-
1 p.
 artikel
338 Treatment of systemic necrotizing vasculitides in patients≥65 years old: Results of the multicenter randomized CORTAGE trial Pagnoux, C.
 2013
 42 4P2 p. 679-680
2 p.
 artikel
339 Treatment related damage in the ANCA-associated vasculitides: An analysis of cohorts from the European Vasculitis Study Group (EUVAS) therapeutic trials Robson, J.
 2013
 42 4P2 p. 744-745
2 p.
 artikel
340 Unilateral vocal cord paralysis as initial manifestation of severe microscopic polyangiitis (MPA) Flores-Suárez, L.F.
 2013
 42 4P2 p. 734-
1 p.
 artikel
341 Unraveling the identity of FoxP3+ regulatory T cells in GPA-patients Abdulahad, W.H.
 2013
 42 4P2 p. 656-657
2 p.
 artikel
342 Upper airway gene expression profiling in granulomatosis with polyangiitis Grayson, P.
 2013
 42 4P2 p. 660-661
2 p.
 artikel
343 Urinary HMGB1 levels are associated with CD4+ T-cells in urine in patients with ANCA-associated vasculitis and active nephritis Silva De Souza, A.W.
 2013
 42 4P2 p. 762-763
2 p.
 artikel
344 Use of an empirically derived cyclophosphamide dosing nomogram for treatment of vasculitis Salama, A.
 2013
 42 4P2 p. 777-778
2 p.
 artikel
345 Use of rituximab in Hispanic patients with severe ANCA associated vasculitis: A 6 years experience in a tertiary centre in Chile Silva, F.
 2013
 42 4P2 p. 777-
1 p.
 artikel
346 Use of the CHCC 2012 definitions in the classification of AAV using the EMA algorithm Abdulkader, R.
 2013
 42 4P2 p. 657-
1 p.
 artikel
347 Validation of the Birmingham Vasculitis activity score (BVAS) and the Vasculitis Damage Index (VDI) in a population of patients with ANCA-associated vasculitis (AASV) in Mexico Ramírez-Assad, C.
 2013
 42 4P2 p. 737-
1 p.
 artikel
348 Vasculitides: Roads traveled and avenue to pursue Guillevin, Loïc
 2013
 42 4P2 p. 491-492
2 p.
 artikel
349 Vessel wall characteristics using high-resolution magnetic resonance imaging in reversible cerebral vasoconstriction syndrome and central nervous system vasculitis Hajj-Ali, R.
 2013
 42 4P2 p. 693-
1 p.
 artikel
350 Vessel wall characteristics using high-resolution magnetic resonance imaging in reversible cerebral vasoconstriction syndrome and central nervous system vasculitis Cerejo, R.
 2013
 42 4P2 p. 692-
1 p.
 artikel
351 Vitamin D level is decreased in patients with Takayasu's arteritis Alibaz-Oner, F.
 2013
 42 4P2 p. 716-717
2 p.
 artikel
352 Wegener or Churg Strauss Saliba, S.
 2013
 42 4P2 p. 715-
1 p.
 artikel
353 Weight loss – a common presentation in a rare disease. IgG4 related disease (IgG4 RD) is an emerging diagnosis not to miss Tosounidou, S.T.
 2013
 42 4P2 p. 740-741
2 p.
 artikel
354 What everybody is doing but no one is talking about: Complementary and alternative medicine (CAM) prevalence in the ANCA SVV population Berg, E.
 2013
 42 4P2 p. 775-
1 p.
 artikel
                             354 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland